Officials with the FDA have approved the first generic robenacoxib tablets for the control of postoperative pain and ...

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are ...

J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Investing in dividend-paying stocks is one of numerous approaches that can help you maximize your portfolio growth, and ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

As an aside, see 3 Risks That Can Make UnitedHealth Stock Unattractive. Additionally, see: MSFT Stock A Winner In 2026? JNJ ...